EUVIMEDEUVIMED entdecken
Crossref

Is adjuvant chemotherapy beneficial in NSCLC patients over 75? Insights from a retrospective analysis

Yohann Vincent, Faustine Enoch, Vanessa Pauly, Anne-Laure Couderc, Pascale Tomasini, Laurent Greillier, Johan Pluvy, Xavier-Benoit D'Journo, Pascal-Alexandre Thomas, Alex Fourdrain, Alice Mogenet

European Journal of Surgical Oncology · 2025

DOI: 10.1016/j.ejso.2025.110307 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Surgical Oncology, 2025. Verfasst von Yohann Vincent und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic and Vascular Surgery, Sainte Anne Military Teaching Hospital, Toulon, France; Department of Thoracic Surgery, Hôpital Nord, As…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit nennt 25 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Lung cancer remains the leading cause of cancer-related mortality worldwide. In resected stage II-III Non-Small Cell Lung Cancer (NSCLC), adjuvant chemotherapy (ACT) improves survival, but its benefit in elderly patients remains unclear due to the lack of dedicated studies. We conducted a retrospective study to assess benefit and predictive factors of ACT in NSCLC patients over 75-years-old. METHODS: We conducted a single-centre retrospective study at Marseille University Hospital using the EPITHOR database. Patients over 75-year-old who underwent anatomical lung resection with a theoretical ACT indication were included between 2013 and 2022. Survival outcomes were compared between ACT and non-ACT groups. The primary endpoint was 5-year mortality without recurrence, with relapse as a competing event. Exploratory outcome were 5-year overall survival and risk factors for recurrence. RESULTS: Among 129 eligible patients, 36 received ACT and 93 did not. ACT group patients were younger, had a more favourable perioperative course, and were more likely to have lymph node-positive disease (N+) (63.9 % vs. 43.0 %, p = 0.031), especially N2 involvement. ACT significantly decreased mortality without recurrence in univariate analysis (HR = 0.257 [95 % CI: 0.080-0.819], p = 0.022), but this benefit disappeared in multivariate analysis (HR = 0.461 [95 % CI: 0.144-1.473], p = 0.191). Similarly, ACT was associated with lower overall mortality in univariate analysis but lost significance in multivariate analysis. CONCLUSION: Oncologists preferentially offer ACT to healthier elderly patients with N+ status. While ACT appears feasible, its benefit must be balanced considering competing risks of death in elderly patients. Identifying high-risk subgroups, including those with N2 disease, is crucial to refine treatment strategies in this population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsHumansAgedFemaleRetrospective StudiesChemotherapy, AdjuvantMaleAged, 80 and overPneumonectomyNeoplasm StagingSurvival RateAge FactorsNeoplasm Recurrence, LocalRisk Factors

Stichwörter der Autor:innen

Adjuvant chemotherapyElderly patientsNon-small cell lung cancerPostoperative

Autor:innen und Institutionen

  • Department of Thoracic and Vascular Surgery, Sainte Anne Military Teaching Hospital, Toulon, France; Department of Thoracic Surgery, Hôpital Nord, Assistance Publique-Hopitaux de Marseille, Aix-Marseille University, Mar…
  • Multidisciplinary Oncology and Therapeutic Innovations Department, Hôpital Nord, Assistance Publique-Hopitaux de Marseille, Aix-Marseille University, Marseille, France.
  • CEReSS-Health Service Research and Quality of Life Center, (EA, 3279) - Aix-Marseille University-Marseille, France.
  • Aix-Marseille University, CNRS, EFS, ADES, Marseille, France; Internal Medicine, Geriatrics and Therapeutic Unit, APHM, France.
  • Multidisciplinary Oncology and Therapeutic Innovations Department, Hôpital Nord, Assistance Publique-Hopitaux de Marseille, Aix-Marseille University, Marseille, France; Aix Marseille University, CNRS, INSERM, CRCM, Mars…
  • Department of Thoracic Surgery, Hôpital Nord, Assistance Publique-Hopitaux de Marseille, Aix-Marseille University, Marseille, France.

Zitieren

APA

Vincent, Y., Enoch, F., Pauly, V., Couderc, A. L., Tomasini, P., Greillier, L., Pluvy, J., D'Journo, X. B., Thomas, P. A., Fourdrain, A., & Mogenet, A. (2025). Is adjuvant chemotherapy beneficial in NSCLC patients over 75? Insights from a retrospective analysis. European Journal of Surgical Oncology. https://doi.org/10.1016/j.ejso.2025.110307

Vancouver

Vincent Y, Enoch F, Pauly V, Couderc AL, Tomasini P, Greillier L, et al. Is adjuvant chemotherapy beneficial in NSCLC patients over 75? Insights from a retrospective analysis. European Journal of Surgical Oncology. 2025. doi:10.1016/j.ejso.2025.110307

BibTeX
@article{Vincent2025,
  author = {Vincent, Yohann and Enoch, Faustine and Pauly, Vanessa and Couderc, Anne-Laure and Tomasini, Pascale and Greillier, Laurent and Pluvy, Johan and D'Journo, Xavier-Benoit and Thomas, Pascal-Alexandre and Fourdrain, Alex and Mogenet, Alice},
  title = {Is adjuvant chemotherapy beneficial in NSCLC patients over 75? Insights from a retrospective analysis},
  journal = {European Journal of Surgical Oncology},
  year = {2025},
  doi = {10.1016/j.ejso.2025.110307}
}
Kostenlos starten →